Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, comments on the current state of next-generation CAR constructs in multiple myeloma (MM), highlighting some constructs she believes hold promise for treating this malignancy. Several dual-targeting CAR strategies are being investigated to improve upon the outcomes achieved with currently available CAR T-cell products. Dr Raje also mentions anitocabtagene autoleucel (anito-cel), an autologous anti-BCMA CAR T-cell therapy with a novel synthetic D-domain binder, which is being investigated in the Phase III iMMagine-3 (NCT06413498) clinical trial. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.